Avenue Therapeutics Valuation
Is 49Y0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 49Y0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 49Y0 (€6) is trading below our estimate of fair value (€111.35)
Significantly Below Fair Value: 49Y0 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 49Y0?
Key metric: As 49Y0 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 49Y0's PB Ratio? | |
|---|---|
| PB Ratio | 2.3x |
| Book | US$1.58m |
| Market Cap | US$3.66m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 49Y0's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.1x | ||
B8FK Biofrontera | 0.9x | n/a | €15.4m |
SBX SynBiotic | 1.8x | 107.0% | €27.9m |
HIGH Cantourage Group | 1.3x | 112.7% | €57.6m |
0RX Redx Pharma | 16.6x | -22.3% | €65.0m |
49Y0 Avenue Therapeutics | 2.3x | 7.9% | €3.7m |
Price-To-Book vs Peers: 49Y0 is expensive based on its Price-To-Book Ratio (2.3x) compared to the peer average (1.6x).
Price to Book Ratio vs Industry
How does 49Y0's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 12 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 12 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: 49Y0 is good value based on its Price-To-Book Ratio (2.3x) compared to the European Pharmaceuticals industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is 49Y0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 2.3x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 49Y0's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | €1,140.93 0% | 95.4% | €2,229.61 | €52.26 | n/a | 2 |
| Nov ’25 | n/a | €1,140.93 0% | 95.4% | €2,229.61 | €52.26 | n/a | 2 |
| Oct ’25 | n/a | €1,140.93 0% | 95.4% | €2,229.61 | €52.26 | n/a | 2 |
| Sep ’25 | n/a | €1,140.93 0% | 95.4% | €2,229.61 | €52.26 | n/a | 2 |
| Aug ’25 | €3.36 | €1,140.93 +33,856.3% | 95.4% | €2,229.61 | €52.26 | n/a | 2 |
| Jul ’25 | €3.32 | €1,140.93 +34,265.4% | 95.4% | €2,229.61 | €52.26 | n/a | 2 |
| Jun ’25 | n/a | €1,140.93 0% | 95.4% | €2,229.61 | €52.26 | n/a | 2 |
| May ’25 | €5.28 | €1,140.93 +21,492.2% | 95.4% | €2,229.61 | €52.26 | n/a | 2 |
| Apr ’25 | n/a | €1,140.93 0% | 95.4% | €2,229.61 | €52.26 | n/a | 2 |
| Mar ’25 | n/a | €1,140.93 0% | 95.4% | €2,229.61 | €52.26 | n/a | 2 |
| Feb ’25 | n/a | €1,140.93 0% | 95.4% | €2,229.61 | €52.26 | n/a | 2 |
| Jan ’25 | n/a | €1,140.93 0% | 95.4% | €2,229.61 | €52.26 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Aspen Pharmacare Holdings
R73.7b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.60
7D
-3.9%
1Y
-0.6%
Collegium Pharmaceutical
US$990.4m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.00
7D
1.4%
1Y
25.0%
Pharming Group
€492.8m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.72
7D
-1.0%
1Y
-31.3%